Abstract 5333
Background
DNA mismatch repair (MMR) deficiency is a genetic abnormality that has important clinical implications related to therapeutic option, familial cancer risk assessment, and checkpoint inhibitor response. It occurs in approximately 15% of colorectal cancers (CRC). Associations between MMR protein expression, microsatellite instability (MSI), and gene mutations remain under investigation.
Methods
Thirty-one FFPE samples from primary CRC patients (pts) were collected for immunohistochemistry (IHC) assay of MMR proteins, PCR-based MSI assay if available and NGS-based panel assay. Genomic alterations including single base substitutions, short and long insertions/deletions, copy number variations, and gene rearrangement were assessed. MSI status were predicted based from NGS data.
Results
Out of 31 sample, 12 CRC were identified as MMR deficiency (dMMR) by IHC including 5 males and 7 females (median age: 66 years), and 19 samples as MMR proficiency (pMMR) including 13 males and 6 females (Median age: 53 years). Eight of the 12 dMMR samples (67%) harbored at least one MMR gene mutations predicted as loss of functions,[u1] including nonsense mutations or truncations in MSH2, MSH6 or MLH1. No MMR gene mutation was detected in any of the 19 pMMR samples (p value<0.001). In addition, 2 BRAF and 6 KRAS hotspot mutations were detected in dMMR samples, and 8 KRAS, 1 BRAF and 1 NRAS mutations in pMMR samples. NGS panel based MSI algorithm successfully predicted the MSI status of all the 31 samples with 100% concordance with the MMR results. Neither copy number variation nor rearrangement was detected. Five pMMR samples were identified as microsatellite stability (MSS) by PCR, 6 dMMR were high level of microsatellite instability (MSI-H), and the rest were failed due to DNA contents.Table: 166P
n | MMR gene mutations (n, %) | KRAS mutations (n, %) | NRAS mutations (n, %) | BRAF mutations (n, %) | NGS MSI-H status (n, %) | |
---|---|---|---|---|---|---|
dMMR (IHC) | 12 | 8 (66.7%) | 6 (50%) | 0 (0%) | 2 (16.7%) | 12 (100%) |
pMMR (IHC) | 19 | 0 (0%) | 8 (42.1%) | 1 (5.2%) | 1 (5.2%) | 0 (0%) |
Conclusions
We observed a significant association between MMR deficiency and MMR gene mutations from deep DNA sequencing. The results suggested that CRC pts with MMR gene mutations could be more likely to have dMMR status.
Clinical trial identification
Legal entity responsible for the study
OrigiMed.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
D. Chen, X. Dong, J. Hu, G. Chirn, W. Shi, M. Yao: Employee: OrigiMed. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract